Does Methylphenidate Treatment for ADHD Increase the Rate of Smoking in Adolescents with Comorbid ADHD, SUD, and Nicotine Dependence? Lead investigator information unavailable.

This ancillary study is related to CTN-0028, "Randomized Controlled Trial of Osmotic-Release Methylphenidate (OROS MPH) for Attention Deficit Hyperactivity DIsorder (ADHD) in Adolescents with Substance Use Disorders."

The purpose of this study is to measure any change in the rate of cigarette smoking among participants in the CTN study 0028 (at the Lexington-Richmond Alcohol and Drug Council (LRADC) site only). The study will use the same urine sample to obtain semi-quantitative cotinine levels using a dipstick urine cotinine measure (NicAlert, Nymox Pharmaceuticals). The hypothesis is that Oros methylphenidate treatment for ADHD among adolescents with comorbid ADHD, substance use disorder, and nicotine dependence will not increase the rate of cigarette smoking. The study will compare self-reported smoking rate and urine cotinine semi-quantitative levels in adolescents receiving Oros methylphenidate vs. those receiving placebo to test the hypothesis above.

LATEST PUBLICATIONS AND DATA

	Find publications in the Library about Protocol CTN-0028a